Join to access to all OVN content. Join for Free
Aspiring MSL Insights: The Do's and Don'ts for MSL Presentations

Aspiring MSL Insights: The Do's and Don'ts for MSL Presentations


Share This Article


Aspiring MSL Insights: The Do's and Don'ts for MSL Presentations

In this video, Michael Pietrack shares three best practices to implement and the three pitfalls to avoid ❌ in your MSL Presentation.

If you’ve been following our Aspiring MSL content, please subscribe to the channel and check out our other playlists. 🔔

1️⃣ Best Practice #1 is to know your slides by heart. Literally, be able to do the presentation without looking at your slides. This will enable you to have a deeper engagement and connection with the audience. And also, know when and what to say as you transition from slide to slide. Not only will this make your presentation very strong , but it will save you in a pinch.

2️⃣ Best Practice #2 is to anticipate questions. So ahead of your presentation, think about what if you were in the audience, what would you want to know? 💬 And if you get a question that you don’t know the answer to, don’t guess the answer. ❌ You want to be able to answer every question, but if you don’t know the answer, simply say, “I want to get you the most accurate answer, so let me follow up with you on that.” And then, after the interview, follow up.

3️⃣ Best Practice #3 is to stick to the time frame they give you. If they ask for a 15-minute presentation, allowing for 15 minutes of Q&A afterward, and you go overtime, that will be a strike against you.

Now of course, the pitfalls are the th ree opposites of those. Reading from the slides , the inability to answer questions , and going over time. But here are three more pitfalls to avoid:

1️⃣ Pitfall #1 if you’re going to use slides that are already created, make sure they are non-proprietary and from the public domain. I had one candidate use slides that had CONFIDENTIAL watermarked on each page. Don’t do that.

2️⃣ Pitfall #2 is presenting outdated data. That is a surefire way to lose the interview, and you would be surprised how often it happens.

3️⃣ Pitfall #3 is don’t data dump. Don’t overwhelm the audience with excessive details. The presentation should be a story that captivates the audience from beginning to end, where the data is used strategically to help the story along.

There are many pitfalls to watch out for, but those are the biggies.

Has this been helpful? If so, subscribe to the channel and make sure to connect with Michael on LinkedIn. When you’re there, join my private LinkedIn group called “KBIC Jobs – Medical Affairs.” Thanks!

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Podcast
Patient Education for Next-Generation Sequencing to Guide Cancer Therapy
OVN Avatar The Oncology Nursing Podcast

Patient Education for Next-Generation Sequencing to Guide Cancer Therapy

Article
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
OVN Avatar Kelvin Chan, Seungree Nam, Bill Evans, Claire de Oliveira Alexandra Chambers, Scott Gavura, Jeffrey Hoch, Rebecca E Mercer, Wei Fang Dai, Jaclyn Beca, Mina Tadrous, Wanrudee Isaranuwatchai

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN